Skip to main content
About us
Our science
Our Pipeline
Partnering
News & Events
Contact
About us
Our science
Our Pipeline
Partnering
News & Events
Contact
Press releases
Go back
Feb 6, 2019
Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
Jan 29, 2019
Galimedix Therapeutics to Participate in the 8th Annual Glaucoma 360 Conference
Dec 11, 2018
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer
Nov 8, 2018
New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects
1
2
3
4